Journal of Autism and Developmental Disorders

, Volume 43, Issue 8, pp 1773–1783

Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study

  • Justine M. Kent
  • Stuart Kushner
  • Xiaoping Ning
  • Keith Karcher
  • Seth Ness
  • Michael Aman
  • Jaskaran Singh
  • David Hough
Original Paper

DOI: 10.1007/s10803-012-1723-5

Cite this article as:
Kent, J.M., Kushner, S., Ning, X. et al. J Autism Dev Disord (2013) 43: 1773. doi:10.1007/s10803-012-1723-5

Abstract

Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5–17 years), received risperidone (low-dose: 0.125 mg/day [20 to <45 kg], 0.175 mg/day [>45 kg] or high-dose: 1.25 mg/day [20 to <45 kg], 1.75 mg/day [>45 kg]) or placebo. Mean baseline (range 27–29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose—(−12.4 [6.5]; p < 0.001), but not low-dose (−7.4 [8.1]; p = 0.164) group, versus placebo (−3.5 [10.7]). Clinical Global Impressions-Severity and Children’s Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently.

Keywords

Autistic disorder Double-blind Placebo-controlled Risperidone 

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Justine M. Kent
    • 1
  • Stuart Kushner
    • 1
    • 4
  • Xiaoping Ning
    • 1
    • 3
  • Keith Karcher
    • 1
  • Seth Ness
    • 1
  • Michael Aman
    • 2
  • Jaskaran Singh
    • 1
  • David Hough
    • 1
  1. 1.Janssen Research & Development, LLCTitusvilleUSA
  2. 2.The Nisonger Center-UCEDDOhio State UniversityColumbusUSA
  3. 3.Purdue PharmaStamfordUSA
  4. 4.CFG Health SystemsMarltonUSA

Personalised recommendations